HealthQuad has officially announced the first closing of its third healthcare-related investment vehicle–the HealthQuad Fund III. The firm has secured financial commitments of ₹550 crore for this initial tranche. The milestone marks a major achievement for the investment manager and is more than a third of the total corpus of ₹1,700 crore with which the new fund has been targeted. The successful raise reflects strong ongoing demand and confidence in the investment community for transformative, technology-enabled healthcare solutions nationwide.

Technology-driven and financial backing 

The initial investment for this third fund came from a widely diversified set of investors. This capital follows a carefully planned mix of existing limited partners who had previously invested in the firm’s previous funds and a host of new investors. 

This new group of investors consists of both domestic and international funds of funds, large institutional investors, and established family offices. Institutional interest will continue to grow because healthcare is recognized as a resilient and high-growth asset class with the potential to provide commercial return and broad social benefit.

The investment thesis for Managed Fund III will be highly specialized and is run by QUADIA, managed by an entirely separate HealthQuad Advisors subsidiary of the Quadia Group. The company will focus on early-stage companies in the business-to-business healthcare industry that intersect with emerging technology. The team will focus its investment capital into high-impact companies that fall under the categories of healthtech, medtech, biopharma technology, and innovative healthcare delivery models.

These target investment sectors closely reflect macroeconomic forecasts for the Indian healthcare sector. The research cited by HealthQuad projects that these technology-focused and specialized health spaces will scale rapidly over the next several years. 

By 2030, their share is estimated to constitute over 40% of the Indian healthcare market, which is set to expand to $600 billion by the end of the year. Through capital deployment in these high-potential areas, Fund III will continue to fund startups that leverage new technology, business models, and product-led solutions to address inequities in the structure of healthcare access, costs, and quality. 

Leadership and capital deployment

Founded in 2016, HealthQuad has long distinguished itself for the identification and endorsement of innovative enterprises in the healthcare domain. The venture capital firm has helped to grow over 18 different businesses through its first two investment funds. Their portfolio has featured prominent players like GoApptiv, Qure.ai, Redcliffe Labs, CureSkin, Strand Life Sciences, Medikabazaar, THB, Wysa, and ekincare. 

In its operations, it has collected experience from all these different businesses, which it uses as the basis for a fresh investment. HealthQuad has already begun deploying assets under the new fund, showing robust operating speed with the first investment it made under Fund III. 

The firm has supported Lifesigns, an artificial intelligence-driven remote patient monitoring technology that aligns with its thesis on tech-driven health care. In tandem with this initial acquisition, the investment manager also noted that its team is currently evaluating several additional opportunities to expand its portfolio of early growth-stage healthcare businesses.

The achievement of successfully launching and closing Fund III is emblematic of a significant shift in structure at the management firm. The Quadria Group was able to preserve the key management staff of Funds I and II after exiting under their corporate partner KOIS in 2025. 

The current seasoned investment team also has Amit Varma, Abrar Mir, and Sunil Thakur, who have rich sector experience. The company has been proactive in upgrading its management team with the addition of Rahul Agarwal and Namit Chugh to provide a suitable leadership structure for the current investment program.

Conclusion

The first close of HealthQuad Fund III for ₹550 crore is a defining moment for India’s healthcare-focused VC community. The firm’s ability to raise more than a third of its ambitious target corpus of ₹1,700 crore from a blend of institutional, domestic, and international investors has only proved the vast potential of technology-enabled medical solutions.

With a team of leadership freshers from Quadria and a proven track record of helping more than 18 portfolio companies, HealthQuad has the momentum to accelerate the next generation of premiumization across healthcare. Its initial investments, such as Lifesigns, as the company allocates capital to fields like healthtech and medtech, will become a crucial force in driving a more accessible, affordable and high-quality healthcare ecosystem capable of catering for India’s projected $600 billion market by 2030.